Analysts Set Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) PT at $3.67

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Get Free Report) has earned a consensus rating of "Hold" from the five ratings firms that are covering the company, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $3.67.

A number of equities analysts recently weighed in on the stock. HC Wainwright restated a "buy" rating and set a $4.00 target price on shares of Lexicon Pharmaceuticals in a research report on Friday, March 28th. Piper Sandler lowered their target price on shares of Lexicon Pharmaceuticals from $10.00 to $6.00 and set an "overweight" rating for the company in a report on Friday, March 7th. Needham & Company LLC reaffirmed a "hold" rating on shares of Lexicon Pharmaceuticals in a research note on Monday, March 3rd. Leerink Partners reissued a "market perform" rating and set a $1.00 target price (down previously from $2.00) on shares of Lexicon Pharmaceuticals in a research report on Tuesday, March 4th. Finally, Wall Street Zen assumed coverage on shares of Lexicon Pharmaceuticals in a research report on Monday, April 21st. They set a "sell" rating on the stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the company. Arizona State Retirement System boosted its stake in Lexicon Pharmaceuticals by 34.4% in the 4th quarter. Arizona State Retirement System now owns 62,976 shares of the biopharmaceutical company's stock worth $47,000 after purchasing an additional 16,136 shares in the last quarter. Swiss National Bank boosted its stake in Lexicon Pharmaceuticals by 34.4% in the 4th quarter. Swiss National Bank now owns 426,600 shares of the biopharmaceutical company's stock worth $315,000 after purchasing an additional 109,100 shares in the last quarter. Teacher Retirement System of Texas boosted its stake in Lexicon Pharmaceuticals by 60.3% in the 4th quarter. Teacher Retirement System of Texas now owns 65,415 shares of the biopharmaceutical company's stock worth $48,000 after purchasing an additional 24,615 shares in the last quarter. Virtu Financial LLC acquired a new stake in Lexicon Pharmaceuticals during the 4th quarter valued at approximately $66,000. Finally, Wellington Management Group LLP lifted its stake in Lexicon Pharmaceuticals by 2.1% during the 4th quarter. Wellington Management Group LLP now owns 747,996 shares of the biopharmaceutical company's stock valued at $552,000 after acquiring an additional 15,249 shares during the period. Hedge funds and other institutional investors own 74.70% of the company's stock.

Lexicon Pharmaceuticals Price Performance

Shares of NASDAQ LXRX traded up $0.02 during midday trading on Friday, reaching $0.75. The stock had a trading volume of 3,608,490 shares, compared to its average volume of 6,691,290. The stock has a 50-day moving average of $0.64 and a 200-day moving average of $0.65. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.22 and a current ratio of 2.22. The company has a market capitalization of $269.49 million, a price-to-earnings ratio of -1.46 and a beta of 1.00. Lexicon Pharmaceuticals has a 12-month low of $0.28 and a 12-month high of $2.45.

Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) last issued its earnings results on Tuesday, May 13th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, topping analysts' consensus estimates of ($0.10) by $0.03. Lexicon Pharmaceuticals had a negative net margin of 568.04% and a negative return on equity of 103.16%. The firm had revenue of $1.26 million during the quarter, compared to analyst estimates of $1.26 million. As a group, research analysts anticipate that Lexicon Pharmaceuticals will post -0.66 EPS for the current fiscal year.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.